Webinar Series Calendar
25 May, 2021 at 3:00pm EDT
7 June, 2021 at 3:00pm EDT
Why Attend
The 5th Animal Health Innovation USA is the must attend networking event in North America for innovators with new solutions to support the detection, prevention or treatment of diseases in animals.
Our mission is to showcase the most exciting investment opportunities in the sector and connect those businesses with financial investors and strategic corporate partners.
Alongside our investment pitches, we include keynote presentations and host CEO-level panel discussions that address the most pressing trends and market dynamics of the animal health, nutrition and productions industries, across all species.
Innovation Showcase
The showcase is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors. 20 start-ups, hand-picked by the Selection Committee, introduce themselves and their innovations and achievements on the main stage.
This year, our presenting companies will be split into two distinguishable sections that will run across the show: Companion animal and petcare and production animal and animal agri-tech.
2021 applications have now closed. Finalists will be announced soon.
The Virtual Experience
Top 10 benefits
- Tailor Your Agenda
- More Audience Participation
- Improved Audience Visibility
- On-Demand Content
- High Quality Speakers
- More Networking Opportunities
- Save Time & Money
- Increased Content
- More insights
- Business Development Opportunities - Talk to our team to find out out more [email protected].
Platform Preview
Animal Health has distinct advantages over human healthcare:
- The research and development process for animal health products is typically shorter and less expensive than for human therapeutics, as animal trials typically can be performed in the target species at an earlier stage, and shorter lifespans result in faster safety assessment and trial completion.
- A substantial portion of animal health R&D is focused on product life-cycle management as opposed to novel drugs, which also leads to less risky pipelines.
- Animal health medicines and vaccines face lower pressure from generic competition when compared to human healthcare peers.
- Animal health is primarily a cash business and does not face the same insurance/third party payer and drug pricing risks that can be an overhang on human therapeutics.
Speakers
Tim Bettington
Alexandre Douzet
Jared Shriver
François Fournier
Julia Loew
Tyre Grant
Bill Zollers
Dr. Bill Zollers, Head of Regulatory Affairs at Argenta, has extensive experience in all facets of veterinary drug development new product registrations within the US and Canada. In his 28+ years, he has led several cross-functional teams to help navigate over 20 veterinary product approvals. During this time, Dr. Zollers has held numerous positions in animal health industry trade organizations, and served on many committees, subcommittees and working groups.
Dr. Zollers earned his PhD degree from the University of Missouri. He joined Argenta, a global CRO and CDMO dedicated to animal health, in February 2020 and is responsibility for oversight of regulatory consultation for drug sponsors.
Matthew Salois
Matthew Rooda
Peter Alberti
Deb Leon
Richard Hobson
Jan Robinson
Jim Penrod
John Butler
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Emily Aston, DVM, PhD
Tom Stein
Phil Hord
Jack A Bobo
Todd B. Richter C.F.A
Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays. From 1999 to 2016 Todd Richter was a Senior Managing Director in the Global Healthcare Corporate & Investment Banking Group at Bank of America Merrill Lynch. From 1981 to 1999, Mr. Richter served as the head of the healthcare services analytical team for Morgan Stanley. Todd Richter earned a B.B.A. in Finance from the College of William & Mary in 1979 and an M.B.A. in Finance with Honors from Indiana University in 1981. Todd was recognized 16 times as a member of the Institutional Investor’s All-America Research Team. He was also listed many times among the Wall Street Journal’s “All-Star” analysts and on the Reuters research poll. Mr. Richter is currently a member of the Board of Directors (Vice Chairman) of Bideawee, one of the nation’s leading animal rescue organizations; a member of the Board of Directors at the Stratton Mountain School (SMS) in Stratton, Vermont, a member of the Board of Directors at Animal Lighthouse Rescue (ALR), and a member of the Dean’s Council for the Kelley School of Business at Indiana University. Finally Mr. Richter is on the Board and faculty of the Columbia University Mailman School of Public Health teaching a course on healthcare consolidation to MPH and MHA candidates.
John Richeson
Dr. John Richeson is currently an Associate Professor of Animal Science and faculty supervisor of the Research Feedlot at West Texas A&M University. He teaches several undergraduate and graduate courses, serves on numerous University and professional committees, and is an advisory board member of four different industry organizations. Dr. Richeson received his BS, MS, and PhD in Animal Science from Oklahoma State University (2000), Texas Tech University (2004), and University of Arkansas (2011), respectively. Research interests include evaluating management, nutritional, and immunological manipulations to improve health and growth of stocker and feedlot cattle. Additional research efforts have focused on evaluation of biomarker and behavior technology to assist in the prediction and early detection of bovine respiratory disease.
Cindy Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
Michael Rohlfsen
George Heidgerken
Sarai Kemp
As VP Business Development for Trendlines Agrifood (Israel) since 2012 and VP Deal Flow for the Trendlines Agrifood Fund (Singapore), Sarai Kemp is responsible for sourcing start-ups, evaluating opportunities, negotiating, and closing investments and working with portfolio companies post-investment. Sarai is a board member on Hargol FoodTech, AgroScout, FruitSpec and AlgaHealth.
Sarai brings more than 20 years’ experience in agricultural, consumer goods, and high-tech industries, including in sales, marketing, and business development for international companies such as Afimilk and Keter Plastic. She has worked intensively with companies in East Asia.
Sarai received an MBA from Haifa University and a B.A. from Tel Aviv University.
Lowell Ackerman
Duane Cantrell
Tom Overbay
Lesley C. Rausch-Derra
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Partners
Associate Partners
Zoetis
Website: www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Elanco
Website: www.elanco.com
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.
TechAccel
Website: http://techaccel.net/
TechAccel, LLC, is a technology and venture development company focused in the agriculture and animal health industry.
Since its founding in 2014, TechAccel sources, invests in and acquires early-stage innovations. Through collaborations with universities and research institutions, TechAccel conducts advancement and de-risking research and development to ready technologies for commercialization.
TechAccel is based in Overland Park, Kansas, with offices in St. Louis, Missouri. For more information, visit www.TechAccel.net. Follow us on Twitter at @Tech_Accel.
IDEXX
Website: www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
Start-Up Development Partner
Paul Dick and Associates (PDA)
Website: pauldickassociates.com
Paul Dick & Associates Ltd. (PDA), founded in 2010, is an animal health consulting firm specializing in (1) the creation of strategic business and product life plans, (2) product development and regulatory affairs strategies, (3) the conduct of GCP studies, (4) the development of white papers to support marketing and sales, (5) business development and fundraising, (6) the acquisition and pitching of new technologies, actives and products, and, (7) various other supporting activities for product development and commercialization. The capabilities of Paul Dick & Associates Ltd. span the research, development, regulatory, and, commercialization continuum for animal pharmaceuticals, biologicals, vaccines, feed ingredients and feeds, and natural/ low risk health products. PDA is the recognized expert for these matters in Canada, as well as for other global markets.
Gold Digital Innovation Partners
Skills Alliance
Website: https://www.skillsalliance.com/
Skills Alliance believe in creating long-term partnerships with their clients as it enables them to provide tailored offerings to match your time and budget requirements.
With a network of offices in London, Zurich, New York, Seattle and Newport Beach and their partnership with Unique Group to cover Latin and South America, they’re able to provide a dynamic combination of local expertise and a global search capability.
They continually evaluate, invest in and implement all suitable new technology (including AI) to ensure you always receive the most cost-effective and efficient fulfilment of your brief. Cutting-edge businesses require a recruitment capability that leads the field.
Klifovet
Website: www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Virbac
Website: https://uk.virbac.com/
Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world’s 7th largest animal health company, Virbac sells products in more than 100 countries, offering a comprehensive and practical range of products and services covering the majority of species and pathologies. Virbac innovation, based on both technological advances and listening to its customers, relies on reactive production facilities which meet the highest international quality standards. For nearly fifty years, these features have allowed the company to build a personalized relationship with veterinarians and farmers around the world.
knoell
As one of the leading service providers for worldwide registration and regulatory compliance knoell offers you efficient services, high flexibility, excellent quality, and reliability. The knoell group has over 600 experts based in 14 countries supporting you to gain and maintain marketability of your substances, active agents, and products - globally! Our team of scientific and regulatory experts can help you in animal health, crop protection, crop nutrition, chemicals, biocides, and medical devices. The knoell approach to acting worldwide is your key to success. Think Globally, Act Locally!
IDEXX
Website: www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
Prelude
Website: https://www.preludedynamics.com/animal-health/
Prelude is the #1 eClinical technology platform in animal research. Companion, livestock, animal registries, pet food, GLP, or any other type of research involving animals can rely on Prelude's 21 CFR Part 11 AND Annex 11 compliant database to collect, analyze, report, and submit clinical data to a regulatory body in an efficient and compliant way. Study data collected using VISION has been used for successful product approvals with CVM, EMA, EPA, and USDA.
Reduce Site’s Learning Curve: When eCRFs look like paper forms, study personnel enter data more intuitively and naturally – reducing errors and increasing technology adoption.
Encourage Remote Participation with eConsent: Tired of managing paper consent documents? Having trouble getting humans into the clinic? VISION eConsent facilitates remote participation.
Enhance the Pet Parent’s Experience: VISION’s ePRO app allows data to be directly entered into a mobile device for quick, contemporaneous capture. Notifications ensure schedule compliance.
Increase Lab Data Integrity: VISION’s one-of-a-kind electronic IDEXX interface posts data directly from the LIMS to the study database, eliminating manual upload and transcription errors.
Clinglobal
Website: https://www.clinglobal.com/
CLINGLOBAL is an Animal Health Services company established during 2016 in Mauritius acting as a contract holding and centralised service provider for the ever expanding “Clin” group of companies.
Our unique business model allows the animal health industry and community to benefit from our simplified contracting solutions by having a customizable all-inclusive approach and the delivery of animal health research projects and services.
Argenta
Website: www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
Bronze Event Partner
Roslin Technologies
Website: https://roslintech.com/
Roslin Technologies is a cutting-edge biotech company that transforms science innovations to provide solutions to global challenges in AgTech and animal health through our expertise in stem cell science and genomic technologies.
Roslin Technologies is a joint venture between the University of Edinburgh and two investment and business development partners with a strong global network and reach. We are based in the Midlothian Science Zone, one of the largest animal science innovation hubs in the world, ensuring that the company is well placed to exploit ground-breaking innovations in animal science and AgTech.
We are currently looking for partners in the animal therapies space with an interest in utilising our Canine induced pluripotent stem cell lines.
Media Partners
IAHJ - International Animal Health Journal
Website: www.animalhealthmedia.com
IAHJ - International Animal Health Journal is a Peer reviewed by our carefully selected editorial advisory panel, and extensive research network, IAHJ reports on Regulations & Validation, Drug Discovery, Development & Delivery, Clinical Research, Nutrition & Infectious Diseases, Custom & Contract Manufacturing, Primary & Secondary Packaging, Logistics & Supply Chain Management, and Marketing & Authorisation of all Drugs, Devices and Food Products that are used in the treatment of animals.
eFeed Link
Website: www.efeedlink.com
Pharma Journalist
Website: www.pharmajournalist.com
Pharma Journalist is a leading international B2B magazine providing the global information and the recent updates in the Pharmaceutical Industry.
Our editorial staff works dedicatedly to provide latest information of Pharmaceutical Industry in the form of articles, news, trends, analysis, market report, press releases, whitepapers, case studies, etc. which helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Various Online marketing services and promotional activities through Pharma Journalist helps companies and organizations to reach their target audience and create brand awareness.
The Agenda
You can download our latest agenda here.
Download the 2021 agenda now. Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Download Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
- Please note that a $70 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in USD
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
Terms & Conditions
In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.
Global Advisory Board
Author:
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Author:
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Author:
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Author:
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Author:
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Author:
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Selection Committee
Author:
Randolph Seidler
Author:
Rob Readnour
Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies, Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets, and Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health.
Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.
Author:
Dino Dedic, CFA
Become a Partner
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
